Clinical trial
Digital Technology to Enhance Access to and Effectiveness of Cancer Genetic Counseling: Effective Familial OutReach Via Tele-genetics (EfFORT) Trial & Supporting Test Result Interpretation and Variant Education (STRIVE) Trial
NCT05420064 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Digital Technology to Enhance Access to and Effectiveness of Cancer Genetic Counseling: Effective Familial OutReach Via Tele-genetics (EfFORT) Trial & Supporting Test Result Interpretation and Variant Education (STRIVE) Trial
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- December 1, 2022
- Completion date
- November 30, 2027
- Enrollment
- 1,000 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
apc gene mutation, atm gene mutation, bard1 gene mutation, bmpr1a gene mutation, brca1 mutation, brca2 mutation, brip1 gene mutation, cdkn2a mutation, chek2 gene mutation, epcam gene mutation, grem1, mlh1 gene mutation, msh2 gene mutation, msh6 gene mutation, palb2 gene mutation, pms2 gene mutation, pold1 gene mutation, pole gene mutation, pten gene mutation, rad51c gene mutation, rad51d gene mutation, smad4